LGC Clinical Diagnostics Seraseq Solid Tumor FFPE DNA Reference Material

LGC Clinical Diagnostics has launched Seraseq Solid Tumor FFPE DNA reference material for assay development, validation, and quality control. It covers 74 variants in 62 genes associated with solid tumors including 37 single-nucleotide variants, 18 deletions, five insertions, and 10 translocations. Of these, 65 variants are targets for US Food and Drug Administration-approved drugs. The material is provided in a lightly fixed FFPE format with variants at clinically relevant allele frequencies.